Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 18, Status: Authorised

Lutathera's approval as the first EMA-authorized radiopharmaceutical for certain neuroendocrine tumors signifies a significant advancement in treatment options, notably enhancing progression-free survival rates. However, concerns over its expanded use in high-grade tumors highlight the importance of ongoing monitoring and evaluation of its efficacy and safety in different patient populations.